Non Small Cell Lung Cancer Metastatic clinical trials

Explore recruiting non small cell lung cancer metastatic clinical trials.

Recruiting non small cell lung cancer metastatic studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Non Small Cell Lung Cancer Metastatic trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Randomized, open-label, Phase 3 study of SAR408701 versus docetaxel in previously treated, metastatic nonsquamous, non-small-cell lung cancer patients with CEACAM5-positive tumors

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase 1b study of an autologous dendritic cell immunotherapy in combination with anti-programmed death-1 treatment in patients with metastatic non-small-cell lung cancer (DARE-LUNG)

Belgium

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator- Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTED46/EVOKE-03)

Greece, Estonia, Latvia, Romania, Germany, Italy +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Multicenter, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-small Cell Lung Cancer With Progressive Disease After Treatment With a Platinum Doublet Chemotherapy and Immunotherapy

Spain, Denmark, Italy, Finland, Germany, Belgium +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater than or Equal to 50% (TroFuse-007)

Portugal, France, Italy, Germany, Spain, Netherlands +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Double-Blind, Phase 3 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination with Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants with Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)​

Germany, Spain, Austria, France, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Non Small Cell Lung Cancer Metastatic trials by city

Non Small Cell Lung Cancer Metastatic in Toronto Non Small Cell Lung Cancer Metastatic in Vancouver Non Small Cell Lung Cancer Metastatic in Montreal Non Small Cell Lung Cancer Metastatic in Calgary Non Small Cell Lung Cancer Metastatic in Edmonton Non Small Cell Lung Cancer Metastatic in Ottawa Non Small Cell Lung Cancer Metastatic in Winnipeg Non Small Cell Lung Cancer Metastatic in Quebec City Non Small Cell Lung Cancer Metastatic in Hamilton Non Small Cell Lung Cancer Metastatic in Kitchener Non Small Cell Lung Cancer Metastatic in London Non Small Cell Lung Cancer Metastatic in Halifax Non Small Cell Lung Cancer Metastatic in New York Non Small Cell Lung Cancer Metastatic in Los Angeles Non Small Cell Lung Cancer Metastatic in Chicago Non Small Cell Lung Cancer Metastatic in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease